BGLC — BIONEXUS GENE LAB CORP

As of Q2 2026, 1 SEC-registered investment managers reported holding BGLC (BIONEXUS GENE LAB CORP) in their latest 13F filings, with a combined reported value of $197 across 101 shares. That is -56.5% by share count (-131 shares) versus the previous quarter, while reported value moved -60.4%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.

Compared with the prior quarter, 1 trimmed, 1 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.

BGLC is classified in the Health Care sector.

All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.